Clik here to view.
Low PSA + Gleason 8 to 10 disease predictive of higher risk, worse survival
It has been hypothesized for some time that men diagnosed with a low PSA level (i.e., < 4.0 ng/ml) but a high Gleason score (of 8, 9, or 10) are at elevated risk for more advanced disease and a...
View ArticleClik here to view.
New multi-biomarker test accurate in detection of clinically significant...
A newly published study in The Lancet has provided some very interesting data on the accuracy of a new, multi-biomarker test in screening 50- to 69-year-old men for risk of prostate cancer. The new...
View ArticleClik here to view.
CMS issues inappropriate proposal to “discourage the use of PSA-based screening”
Apparently our friends at the Centers for Medicare and Medicaid Services (CMS) have misunderstood the details of the D recommendation about PSA screening for prostate cancer issued by the U.S....
View ArticleClik here to view.
Prostate Cancer International submits comment on CMS proposal to discourage...
Prostate Cancer International and The “New” Prostate Cancer InfoLink have never been supportive of the use of annual, mass, population-wide PSA screening of men over the ages of about 40 or 50 years as...
View ArticleClik here to view.
Getting a repeat PSA test prior to biopsy … value now confirmed
For quite a while now The “New” Prostate Cancer InfoLink and many others have been advising men who get a single, somewhat elevated PSA test result to get that test repeated before they make any...
View ArticleClik here to view.
The prognostic value of PSA kinetics in untreated men with prostate cancer
The question of whether PSA kinetics (e.g., PSA doubling time and PSA velocity) can be used to accurately project risk for prostate cancer progression and mortality is still not definitively known...
View ArticleClik here to view.
A highly qualified “thank you” to Drs. Welch and Albertsen — maybe?
The prostate cancer patient community should be aware of an “op-ed” in today’s New York Times by Drs. Gilbert Welch and Peter Albertsen arguing that Medicare should continue to let individual...
View ArticleClik here to view.
What does a very high PSA at diagnosis tell us?
Probably because of high level of research funding as a consequence of the Movember Foundation‘s initiatives, Australia is increasingly providing us with interesting data on the diagnosis, management,...
View ArticleClik here to view.
PSA testing among black males here in America
It is well understood that African-American men and other “black” males of African ethnic origin are at greater risk for prostate cancer (at least here in America) than are non-Hispanic “white” males....
View ArticleClik here to view.
PCPC3 applauds Medicare decision re use of PSA test
The following statement was issued this afternoon by PCPC3 — the patient-centered prostate cancer collaborative coalition: PCPC3 and its members are extremely pleased to learn that a key advisory group...
View ArticleClik here to view.
And back to the screening controversy, yet again …
Four very recent articles and presentations have addressed issues relevant to the use of the PSA test in testing/screening for risk of prostate cancer. An extremely detailed article by Roth et al. in...
View ArticleClik here to view.
Clinician characteristics affect likelihood of PSA testing in older men
A new article in JAMA Internal Medicine has quantified (to some extent) how characteristics of clinicians affect the probability of older men being given PSA tests within the Veterans Administration...
View ArticleClik here to view.
Citrate concentrations in seminal fluid and risk for prostate cancer
Another paper to be presented as a late-breaking poster at the upcoming annual meeting of the American Urological Association in San Diego suggests that citrate concentrations in seminal fluid may be a...
View ArticleClik here to view.
Optimal nadir PSA after salvage cryotherapy for radiorecurrent prostate cancer
According to a new article in the Journal of Endourology, the authors have identified an optimal PSA nadir level after whole-gland salvage prostate cryoablation among patients with recurrent prostate...
View ArticleClik here to view.
Another reason to love your “bounces”
PSA “bounces” are (relatively small) increases in a patient’s PSA level from a lowering level after completion of primary radiation therapy The size of such bounces can vary significantly — from as...
View ArticleClik here to view.
PCPC3 notes revisions to USPSTF research plan on PSA screening
PCPC3 — the patient-centered prostate cancer collaborative coalition — has just issued a statement about the revised research plan issued by the U.S. Preventive Services Task Force (USPSTF) in...
View ArticleClik here to view.
The systemic problems of the PCLO trial of PSA screening
A Letter to the Editor published in this week’s issue of the New England Journal of Medicine has, yet again, pointed out that the US-based PCLO trial was badly flawed and was never, in fact, a trial of...
View ArticleClik here to view.
Is standardization of the PSA cutpoint for biochemical recurrence after...
A paper just published in this month’s issue of the Journal of Urology has suggested that the true cutpoint for PSA levels indicative of biochemical recurrence in the highest number of patients is...
View ArticleClik here to view.
The politics of PSA testing
We continue to see a steady stream of articles in the cancer literature that appears to be designed to influence the thinking of the U.S. Preventive Services Task Force (USPSTF) as they reconsider the...
View ArticleClik here to view.
Informed patient counseling and the effect on PSA testing
We know that a family history of prostate cancer and the presence of certain genetic/genomic markers are associated with increased risk for prostate cancer in general and for some types of clinically...
View Article